| Literature DB >> 31287990 |
Nivine Srour1, Sofiane Y Mersaoui1, Stéphane Richard2.
Abstract
In this issue of Cancer Cell, Fedoriw and colleagues characterize a potent reversible inhibitor of type I PRMTs, GSK3368715, with anti-proliferative effects on numerous cancer types. Using a combination of GSK3368715 with PRMT5 inhibitors, the authors show that a threshold of overall arginine methylation reduction needs to be achieved for synergistic anti-tumor activity.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31287990 DOI： 10.1016/j.ccell.2019.06.004
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743